Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2020-03-09 Director's Dealing
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document is explicitly titled 'Directors’ Dealings' and contains a 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'. It details the name of the person (Stephan Sturm), their position ('Member of the managing body'), and the specifics of the transaction, including the instrument type ('Share'), nature ('Acquisition'), price, volume, and date. This directly corresponds to the definition of Director's Dealing (DIRS).
2020-03-09 English
Declaration of Voting Results & Voting Rights Announcements 2020
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Notification of Major Holdings' and explicitly mentions 'Voting Rights Announcements' at the top. It details changes in the percentage of voting rights held by a specific entity (DWS Investment GmbH) in Fresenius SE & Co. KGaA, referencing German Securities Trading Act (WpHG) sections. This content directly corresponds to the definition of reporting changes in significant share ownership thresholds, which aligns best with the 'Major Shareholding Notification' category (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the core content is the change in holding percentage, not the results of a vote (DVA).
2020-03-06 English
Roadshow Paris
Investor Presentation Classification · 100% confidence The document is titled "Roadshow Paris" and dated March 04, 2020. It contains extensive slides detailing the company's global sales base, track record, segment performance (Fresenius Medical Care, Kabi, Helios, Vamed), growth drivers, strategy, ESG priorities, capital deployment, dividend policy, and a review of FY/19 results with outlooks for 2020-2023. This structure is characteristic of an Investor Presentation (IP) used for roadshows or investor days, rather than a formal regulatory filing like a 10-K or a brief Earnings Release (ER). It is a detailed presentation for investors.
2020-03-04 English
Morgan Stanley – European MedTech & Services Conference
Investor Presentation Classification · 100% confidence The document is titled "Morgan Stanley European MedTech & Services Conference" and contains numerous slides detailing the company's business segments (Fresenius Medical Care, Kabi, Helios, Vamed), global trends, growth targets (2020-2023), ESG priorities, capital deployment, and a review of FY/19 results. It includes forward-looking statements and financial projections. This structure is characteristic of an Investor Presentation (IP) given at a conference, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which typically focuses only on the period's results. The presence of detailed segment analysis and strategy outlook strongly points to an Investor Presentation.
2020-03-03 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document explicitly contains the header "Directors’ Dealings" and the title "DGAP-DD: Fresenius SE & Co. KGaA english". It details transactions (Acquisition) made by a "person discharging managerial responsibilities" (Stephan Sturm, Member of the managing body) involving company shares, including prices, volumes, and transaction dates. This perfectly matches the definition for Director's Dealing (Code: DIRS). The document length is short (2374 chars), but the content is the primary disclosure itself, not an announcement of a report, thus DIRS is the correct classification.
2020-03-02 English
DGAP-DD: Fresenius SE & Co. KGaA english
Director's Dealing Classification · 100% confidence The document explicitly uses the header "Directors’ Dealings" and contains detailed information regarding a transaction by a "person discharging managerial responsibilities" (Stephan Sturm, Member of the managing body) involving the acquisition of company shares. This directly matches the definition for Director's Dealing (DIRS). The document structure and content are typical of insider transaction disclosures.
2020-03-02 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.